Abstract
The cost-effectiveness of low-dose computed tomography (LDCT) screening for lung cancer depends on contextual factors and the target screening program. Combined LDCT screening for the Big-3 diseases (lung cancer, cardiovascular disease (CVD) and chronic obstructive pulmonary disease (COPD)) could potentially increase health benefits at marginal additional costs. This study aims to estimate the cost-utility of Big-3 screening compared to usual care (no-screening).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
